Wednesday, November 27, 2024 12:48:06 PM
sleven, ok, I certainly don't know what management knows. I wish I did, but I have yet to think of a scenario where I would be going down the present path. What's the number one question about AMRN?
It comes down to are we going to get bought out. If I were CEO for a day, that's the first thing I want to know. What are the prospects of getting bought out in the next 2-3 years. If we are, I can assume roughly $450M in sales over the next 3 years to go with $550M in assets. That's almost $1B. Start the buyback immediately! We are getting bought out and that gives us leverage. Now, if there is no interest in a bo, then I am going back to all the BP's and negotiate a deal with one of them that works in the space. I don't even care if I get no money up front and a modest royalty that increases with volume. The costs of the EU are gone. I am turning to the US and am cutting operating expenses significantly. Our operating expenses are higher than say Hikma's generic division. Why? It would be a dramatic change that should quickly cut costs and give us the ability to buy back shares on a continuous basis. Ok, I get it. I am making many assumptions and what I propose may not be where we are at, but this is the type of strategic thinking that can get us out of this mess. Again, I see nothing that is turning this around. I hope there is, because the path we are on will end in failure.
It comes down to are we going to get bought out. If I were CEO for a day, that's the first thing I want to know. What are the prospects of getting bought out in the next 2-3 years. If we are, I can assume roughly $450M in sales over the next 3 years to go with $550M in assets. That's almost $1B. Start the buyback immediately! We are getting bought out and that gives us leverage. Now, if there is no interest in a bo, then I am going back to all the BP's and negotiate a deal with one of them that works in the space. I don't even care if I get no money up front and a modest royalty that increases with volume. The costs of the EU are gone. I am turning to the US and am cutting operating expenses significantly. Our operating expenses are higher than say Hikma's generic division. Why? It would be a dramatic change that should quickly cut costs and give us the ability to buy back shares on a continuous basis. Ok, I get it. I am making many assumptions and what I propose may not be where we are at, but this is the type of strategic thinking that can get us out of this mess. Again, I see nothing that is turning this around. I hope there is, because the path we are on will end in failure.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
